NorstellaLinQ: The Obesity Coding Gap: Identifying the Patients Claims Data Misses

Diagnosis codes capture only a fraction of the true obesity population. Measured against recorded BMI from height and weight, the majority of clinically obese patients are not identified through claims data alone, creating blind spots for patient identification, market sizing, and real-world evidence generation. In this infographic, find out: How obesity diagnosis coding is undercouting […]

Busting Real-World Data and AI Myths

rwd-after-dark

Artificial intelligence is transforming how life sciences organizations unlock the full value of real-world data—but success depends on more than AI alone. In this episode of Real-World Data After Dark, Daniel Chancellor is joined by Kris Kaneta, Chief Product & Innovation Officer at Norstella, and Ted Search, Chief Real-World Data & Analytics Officer at Norstella, […]

From Data Access to Evidence Usability: Connecting Payer Policy, Real-World Data, and Clinical Context to Close the Evidence Gap

from-data-access-evidence-usability

Real-world data has never been more abundant, but data alone doesn’t tell the full patient story. In this episode of tHEORetically Speaking, Becky Hollenberg, Senior Real-World Data Strategy Lead at Norstella, explores why connecting claims, electronic medical records (EMRs), clinical notes, laboratory data, and payer policy information is essential to generating meaningful real-world evidence. The conversation […]

How AI is Changing Clinical Development

how-ai-changing-clinical-development

AI is no longer a peripheral tool in drug development. It is reshaping how trials are designed, run, and completed, and the pace of change is accelerating. In this episode of the Drug Discovery World Podcast, Suzanne Caruso, President and General Manager of Clinical, Regulatory and Strategic Intelligence at Norstella, speaks with host Bruno Quinney […]

Rewriting the Clinical and Commercial Rulebook with Real-World Data

rewriting-clinical-commercial-rulebook-real-world-data

This webinar explores how real-world data (RWD) and AI are transforming clinical development, evidence generation, and commercialization, particularly in rare diseases and brain cancer. Speakers discuss how integrated RWD helps identify geographically dispersed patients, optimize trial design, support biomarker-driven targeting, and improve commercial strategy, while AI and NLP enable deeper analysis of unstructured clinical data […]

How Real-World Data is Transforming GLP-1 Strategy, and the Keys to Launch Success

how-real-world-data-transforming-glp-1-strategy-keys-launch-success

This webinar explores how integrated real-world data (RWD) and AI are reshaping commercial strategy for GLP-1 therapies as the obesity and cardiometabolic markets rapidly expand. Speakers discuss how combining EMR, claims, payer, and prescription data helps manufacturers identify untreated patient populations, monitor launches in near real time, understand prescribing and channel trends, and address access […]

Trustworthy and Novel AI in Clinical Trial Planning

kris-kaneta-feature

This pharmaphorum podcast explores how AI is transforming drug development and commercialization, with Norstella Chief Product Officer Kris Kaneta discussing the growing role of clinical AI powered by robust patient-level data. Kaneta explains how AI can move beyond administrative efficiency to deliver real strategic recommendations for clinical trials, commercialization and decision-making across the product lifecycle. […]

NorstellaLinQ: Identify Obesity Treatment Opportunity Before the Market Does

norstellalinq-identify-obesity-treatment-opportunity-before-market-does

For GLP-1 therapies, traditional data sources alone aren’t enough to understand the full patient journey. NorstellaLinQ’s 74 billion data points give you the full picture and help you optimize GLP-1 launch strategies in real time. This infographic shows how NorstellaLinQ: Unlocks key information on patients, providers, systems, and payers Uncovers prescribing trends for GLP-1s weeks […]

Using Real-World Data to Redefine Evidence for Ultra-Rare Diseases

real-world-data-redefine-evidence-ultra-rare-diseases

In ultra-rare diseases, where traditional control arms are often impractical, regulators still require meaningful context to interpret trial outcomes. Here’s how a biotech company leveraged NorstellaLinQ to build a regulatory-grade real-world control dataset that combined deep unstructured clinical notes, AI-enabled data curation, and rigorous propensity score matching. By creating a highly comparable real-world cohort, the […]

Inside the Norstella Panel: The Engine Behind Smarter Access Decisions

panel-engine-behind-smarter-access-decisions

The Norstella Panel puts you in the room with the people who decide. Active P&T leaders. Payer and PBM decision makers. Provider and IDN influencers. The voices shaping coverage in real time. As the industry’s leading partner in access, Norstella delivers reach others simply can’t match. Download the infographic to see the scale, specialization, and […]

Norstella Brands